Abstract:The transient receptor potential vanilloid type 1 (TRPV1), a non-selective cation channel, is known for its essential role in the pathogenesis of various pain conditions such as nerve damage induced hyperalgesia, diabetic neuropathy and cancer pain. Therefore, TRPV1 is considered as a promising target for the development of new anti-inflammatory and analgesic drugs. In the present study, a theoretical study on the functionalities of the molecular interactions between 236 active ligands and TRPV1 was carried out, using three-dimensional quantitative structure-activity relationships (3D-QSAR), molecular docking and molecular dynamics (MD) simulation approaches. The ligand-based CoMSIA model (obtained by use of a random division method for splitting the training and test sets) exhibits optimum predictivity (Q(2) = 0.522, R(ncv)(2) = 0.935, R(pred)(2) = 0.839). The results show that the models are useful tools for the prediction of the test sets as well as newly designed structures against TRPV1 activity. In addition, to verify the rationality of the random division method for splitting the dataset, we also used a self-organizing map (SOM) division approach for establishing the QSAR models. Interestingly, the obtained optimal CoMSIA model based on the SOM division exhibits almost the same proper statistical results (Q(2) = 0.521, R(ncv)(2) = 0.929, R(pred)(2) = 0.829) as the random division-derived model, proving the reasonability of both division methods for building the models. The contour plots of molecular fields along with docking and MD simulation have identified several key structural requirements responsible for the activity. The present work provides extremely useful guidelines for future structural modifications of this class of compounds towards the development of superior TRPV1 antagonists. The new computational insights presented in this study are expected to be valuable for the guideline and development of new potent TRPV1 antagonists.

Phenylquinoline Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of 1-(2-Phenylquinoline-4-carbonyl)-n-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide.

Design, Synthesis and Biological Activities of 2,3-Dihydroquinazolin-4(1h)-one Derivatives As TRPM2 Inhibitors.

Discovery of (S)–N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist

Design, synthesis and biological evaluation of N 1 -(isoquinolin-5-yl)-N 2 -phenylpyrrolidine-1,2-dicarboxamide derivatives as potent TRPV1 antagonists.

Design, Synthesis and Biological Evaluation of Novel 2,3,4,9-Tetrahydro-1h-pyrido[3,4-b]indole Triazole Derivatives As Potent TRPV1 Antagonists.

Design, Synthesis and Biological Activities of Benzo[d]imidazo[1,2-A]imidazole Derivatives As TRPM2-specfic Inhibitors

Synthesis of Carbamide Derivatives Bearing Tetrahydroisoquinoline Moieties and Biological Evaluation As Analgesia Drugs in Mice

Discovery of Potent and Selective Transient Receptor Potential Vanilloid 1 (TRPV1) Agonists with Analgesic Effects in Vivo Based on the Functional Conversion Induced by Altering the Orientation of the Indazole Core.

Synthesis and Biological Evaluation of Novel 6,7-Dihydro-5h-cyclopenta[d]pyrimidine and 5,6,7,8-Tetrahydroquinazoline Derivatives As Sigma-1 (σ1) Receptor Antagonists for the Treatment of Pain.

Novel phenylpiperazine derivatives as potent transient receptor potential vanilloid 1 antagonists

Synthesis and Biological Evaluation of Dihydroisoquinoline-2(1H)- Carbothioamide Derivatives As TRPV1 Antagonists

Study on Chemical Modification and Analgesic Activity of N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl) Piperazine-1-carboxamide.

Novel Benzodiazepines Derivatives As Analgesic Modulating for Transient Receptor Potential Vanilloid 1.

Synthesis and Biological Evaluation of a Novel Sigma-1 Receptor Antagonist Based on 3,4-Dihydro-2(1h)-quinolinone Scaffold As a Potential Analgesic.

Novel piperazine urea derivatives as highly potent transient receptor potential vanilloid 1 (TRPV1) antagonists

Synthesis of Analogues of BCTC Incorporating a Pyrrolidinyl Linker and Biological Evaluation As Transient Receptor Potential Vanilloid 1 Antagonists

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

In silico research to assist the investigation of carboxamide derivatives as potent TRPV1 antagonists

Isoquinolone derivatives as lysophosphatidic acid receptor 5 (LPA5) antagonists: Investigation of structure-activity relationships, ADME properties and analgesic effects

Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain.

Discovery of N -(1-(2-hydroxyethyl)quinolin-2-one)- N '-(1-phenyl-1H-pyrazol-5-yl)methyl) urea as Mode-Selective TRPV1 antagonist